SEC Company Response from PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648) (PVLA) — Jun 26, 2015
PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648)
Date: June 26, 2015 · CIK: 0001583648 · Accession: 0001193125-15-237157
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-204833
Letter
Acceleration Request
June 26, 2015
U.S. Securities and Exchange Commission
Division of Corporation Finance
101 F Street NE Mailstop 4720
Washington, D.C.
Attention: Jeffrey P. Riedler
Assistant Director
Re: Pieris Pharmaceuticals, Inc.
Registration Statement on Form S-1 (File No. 333-204833)
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we, the representatives of the several underwriters, wish to advise you that between June 17, 2015 and June 25, 2015, approximately 1,379 copies of the Preliminary Prospectus dated June 17, 2015 were distributed as follows:
•
10 to prospective underwriters and dealers;
•
487 to institutional investors; and
•
882 to individuals.
The undersigned, as representatives of the several underwriters, have and will, and each underwriter and dealer has advised the undersigned that it has and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, we hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 9:00 a.m., Washington, D.C. time, on June 29, 2015 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
OPPENHEIMER & CO. INC.
Show Raw Text
CORRESP
1
filename1.htm
Acceleration Request
June 26, 2015
U.S. Securities and Exchange Commission
Division of Corporation
Finance
101 F Street NE Mailstop 4720
Washington, D.C.
20549
Attention: Jeffrey P. Riedler
Assistant Director
Re:
Pieris Pharmaceuticals, Inc.
Registration Statement on Form S-1 (File No. 333-204833)
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we, the representatives of the several underwriters, wish to advise you that between June 17,
2015 and June 25, 2015, approximately 1,379 copies of the Preliminary Prospectus dated June 17, 2015 were distributed as follows:
•
10 to prospective underwriters and dealers;
•
487 to institutional investors; and
•
882 to individuals.
The undersigned, as representatives of the several underwriters, have and will, and each
underwriter and dealer has advised the undersigned that it has and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, we hereby join in the request of the registrant that the effectiveness of the
above-captioned Registration Statement, as amended, be accelerated to 9:00 a.m., Washington, D.C. time, on June 29, 2015 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
OPPENHEIMER & CO. INC.
JMP SECURITIES LLC
As representatives of the
several Underwriters
OPPENHEIMER & CO. INC.
By:
/s/ Douglas Cameron
Name:
Douglas Cameron
Title:
Head of Equity Capital Markets
JMP SECURITIES LLC
By:
/s/ Stephen Ortiz
Name:
Stephen Ortiz
Title:
Managing Director
cc:
Stephen S. Yoder, Pieris Pharmaceuticals, Inc.
Darlene Deptula-Hicks, Pieris Pharmaceuticals, Inc.
William C. Hicks, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Marc Mantell, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Thomas Levato, Goodwin Procter LLP
[Signature Page to Underwriters’ Acceleration Request Letter]